Clinical trials: Elderly Infection
Bacterial Infections
To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.
This is a Phase 1, randomized, double-blind, placebo-controlled study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-min (± 3 min) IV infusion in healthy adult young females and…
- Trial name
- NCT04801043
- Testing
- XNW4107, Imipenem/Cilastatin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons
The purpose of this study is to determine the immunogenicity and tolerability of Fluval AB trivalent influenza vaccine in adults and elderly people.
- Trial name
- NCT01404182
- Testing
- Vaccination with Fluval AB influenza vaccine
- Where
- 2 sites in Hungary
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older.
- Trial name
- NCT00760617
- Testing
- GSK Bio's influenza vaccine GSK2186877A, Fluarix
- Where
- 25 sites in Germany, Netherlands and 1 more
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above
The objective is to describe the safety profile after 1 dose of VaxigripTetra inj. administered in subjects aged 3 years old and above under routine clinical practice.
- Trial name
- NCT05406180
- Testing
- VaxigripTetra inj.
- Where
- 10 sites in South Korea
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational…
- Trial name
- NCT03282240
- Testing
- QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
- Where
- 36 sites in United States
- Volunteers
- 2,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Fungal Infection
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
Due to the poor outcome of patients with invasive fungal infections (IFI), a more effective prevention of these infections in such patients is wanted.
- Trial name
- NCT00386997
- Testing
- liposomal amphotericin B (AmBisome®)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Pneumococcal Infections
Phase I Clinical Trial of a Candidate PCV13 in Healthy People
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.
- Trial name
- NCT05602480
- Testing
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
SARS-CoV-2
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283…
- Trial name
- NCT04813796
- Testing
- mRNA-1283, mRNA-1273
- Where
- 5 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Herpes Zoster
Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects
Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles).
- Trial name
- NCT00434577
- Testing
- Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad-spectrum influenza vaccine based upon the internal influenza…
- Trial name
- NCT06779981
- Testing
- Nasopharyngeal swabs
- Where
- Belgium
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Osivax
Herpes Simplex
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered…
- Trial name
- NCT04762511
- Testing
- Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A)
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults
In the present study the immunogenicity, reactogenicity and safety of recombinant hepatitis B vaccines with and without MPL will be evaluated in older healthy subjects
- Trial name
- NCT00697242
- Testing
- Engerix™-B, Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
- Where
- 4 sites in Austria, Belgium and 2 more
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
The aim of the study is to document immunogenicity and safety of VRVg in a pre-exposure regimen in healthy children and adolescents aged 2 to 17 years.
- Trial name
- NCT01930357
- Testing
- Purified Vero Rabies Vaccine Serum Free (VRVg), Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),
- Where
- 2 sites in Philippines
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Interpandemic Influenza
Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
Trial for annual approval of interpandemic influenza vaccines
- Trial name
- NCT00734734
- Testing
- Seasonal Influenza Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the…
- Trial name
- NCT07220109
- Testing
- RSVPreF3 OA vaccine
- Where
- 15 sites in China
- Volunteers
- 750 people
- Sponsor
- GlaxoSmithKline
COVID-19
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess immunogenicity and safety of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and…
- Trial name
- NCT04990544
- Testing
- 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose
- Where
- China
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Human Immunodeficiency Virus (HIV) Infection
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to <12 years and weighing <45 kg, who are treatment-naive (TN) or have been…
- Trial name
- NCT04375800
- Testing
- Doravirine, 2 NRTIs, DOR/3TC/TDF
- Where
- 26 sites in United States, Colombia and 6 more
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC
Mumps
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine, live (MMRV).
- Trial name
- NCT04364399
- Testing
- Mumps vaccine, measles, mumps and rubella combined vaccine, live
- Where
- China
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.